According to our new research study on “Proteomics Market Forecast to 2030 - COVID-19 Impact and Global Analysis - by Product & Service, Application, and End User,” the market is anticipated to grow from US$ 27.07 billion in 2022 and is projected to reach US$ 75.03 billion by 2030; it is expected to register a CAGR of 13.6% during 2022-2030. Market growth is attributed to the proliferating cases of chronic diseases and the growing prominence of nano proteomics. Growing technological advancements and R&D expenditure will likely provide growth opportunities for the proteomics market. However, the high costs of instruments and the dearth of skilled personnel hinder the growth of the proteomics market.
Proteomics, the detailed analysis of proteins, has become a significant field to study drug development, therapy, prognosis, and disease characterization. Proteomics technologies help with both infectious and noninfectious disease detection and therapy. The current proteomic methodologies are being made more reliable, biocompatible, specific, and reproducible through the use of nanotechnology as a technological platform. The shortcomings of conventional proteomic techniques are greatly assessed with the use of nanomaterials to enhance the quality of proteomic techniques by protein manipulation. In the pharmaceutical field, proteomics studies drug effects or the mechanism of toxicity. They are also widely used to identify and confirm the effectiveness of biomarkers.
North America accounted for a major share of the global proteomics market in 2022. The North American proteomics market is segmented into the US, Canada, and Mexico. The key factors driving the market growth in this region is the increasing investments in the development of structure-based drug design, demand for high-quality research tools for data reproducibility, growth in omics research, etc. Attention is being paid to the development of tailor-made treatments. Partnerships and collaborations between major regional companies also contribute to the market expansion in the region. For example, Thermo Fisher Scientific Inc. and Symphogen have collaborated to develop verified platform processes for optimized characterization and quality monitoring of complex therapeutic proteins. Also, proteomics research is at its peak in countries like the US.
The increasing investments in research and development in proteomics are fostering market growth. The US National Institutes of Health (NIH) gave US$ 37 billion for biomedical research. This funding will aid in studying the fundamental mechanisms of disease development, identifying biomarkers that indicate the presence of a disease, or identifying the gene or protein that causes the disease. The Novo Nordisk Foundation granted the University of Copenhagen a grant of up to US$ 1.5 million to build a mass spectrometry facility, an important step toward protein research. The market quickly gained momentum after the outbreak of COVID-19.
Key players are crucial in improving people's access to quality healthcare and medicines in developing countries, which also expands their economic prospects, and they are also working to increase economic opportunities by creating more jobs, making significant investments, influencing public policy, and providing trainings. The pharmaceutical industry has a significant impact on the growth of economic opportunities in developing countries. In recent years, pharmaceutical companies have achieved excellent financial results. For example, Thermo Fisher Scientific, Inc. posted record profits last year, and future performance is predicted to be even better. The market will continue to flourish as several biopharmaceutical companies are emerging as key players and various R&D activities are being conducted, thereby providing growth opportunities for the global market.
Reagents & kits, consumables, and strips are increasingly used for studying various biological materials in research universities, research institutions, and other areas. Government initiatives in the field of proteomics and genomics are propelling research activities in disease diagnostics. Technical advancements in advanced instruments, such as 3D electrophoresis protein analyzers, which increase biological research's speed, efficiency, and productivity, are also propelling the demand for reagents and consumables. These factors are contributing to the growing proteomics market size for the segment.
Leading players are implementing strategies such as expansion, partnership, launch of new products, and acquisition of a new customer base for tapping prevailing business opportunities.
Proteomics, the detailed analysis of proteins, has become a significant field to study drug development, therapy, prognosis, and disease characterization. Proteomics technologies help with both infectious and noninfectious disease detection and therapy. The current proteomic methodologies are being made more reliable, biocompatible, specific, and reproducible through the use of nanotechnology as a technological platform. The shortcomings of conventional proteomic techniques are greatly assessed with the use of nanomaterials to enhance the quality of proteomic techniques by protein manipulation. In the pharmaceutical field, proteomics studies drug effects or the mechanism of toxicity. They are also widely used to identify and confirm the effectiveness of biomarkers.
North America accounted for a major share of the global proteomics market in 2022. The North American proteomics market is segmented into the US, Canada, and Mexico. The key factors driving the market growth in this region is the increasing investments in the development of structure-based drug design, demand for high-quality research tools for data reproducibility, growth in omics research, etc. Attention is being paid to the development of tailor-made treatments. Partnerships and collaborations between major regional companies also contribute to the market expansion in the region. For example, Thermo Fisher Scientific Inc. and Symphogen have collaborated to develop verified platform processes for optimized characterization and quality monitoring of complex therapeutic proteins. Also, proteomics research is at its peak in countries like the US.
Growing Technological Advancements and R&D Expenditure to Provide Market Opportunities in the Future
Manufacturers in the proteomics industry are focused on providing new methods and devices for disease diagnosis. Companies such as Agilent Technologies, Inc. have recognized the advantages of using technology out-licensing strategies to focus on developing products for protein analysis. The absolute quantification of protein-based diagnostics was made possible through the use of proteomics technology. Key proteomic services and other technologies, including microarray, X-ray crystallography, spectroscopic techniques, chromatography, electrophoresis, and surface plasma resonance systems, form the foundation of the proteomics market.The increasing investments in research and development in proteomics are fostering market growth. The US National Institutes of Health (NIH) gave US$ 37 billion for biomedical research. This funding will aid in studying the fundamental mechanisms of disease development, identifying biomarkers that indicate the presence of a disease, or identifying the gene or protein that causes the disease. The Novo Nordisk Foundation granted the University of Copenhagen a grant of up to US$ 1.5 million to build a mass spectrometry facility, an important step toward protein research. The market quickly gained momentum after the outbreak of COVID-19.
Key players are crucial in improving people's access to quality healthcare and medicines in developing countries, which also expands their economic prospects, and they are also working to increase economic opportunities by creating more jobs, making significant investments, influencing public policy, and providing trainings. The pharmaceutical industry has a significant impact on the growth of economic opportunities in developing countries. In recent years, pharmaceutical companies have achieved excellent financial results. For example, Thermo Fisher Scientific, Inc. posted record profits last year, and future performance is predicted to be even better. The market will continue to flourish as several biopharmaceutical companies are emerging as key players and various R&D activities are being conducted, thereby providing growth opportunities for the global market.
Product & Service -Based Insights
Based on product & service, the proteomics market is divided into instrumentation technologies, reagents & consumables, and software & services. The reagents & consumables segment held the largest market share in 2022 and is likely to register the highest CAGR of 14.1% during 2022-2030.Reagents & kits, consumables, and strips are increasingly used for studying various biological materials in research universities, research institutions, and other areas. Government initiatives in the field of proteomics and genomics are propelling research activities in disease diagnostics. Technical advancements in advanced instruments, such as 3D electrophoresis protein analyzers, which increase biological research's speed, efficiency, and productivity, are also propelling the demand for reagents and consumables. These factors are contributing to the growing proteomics market size for the segment.
Application -Based Insights
The market, based on application, is divided into clinical diagnostics, drug discovery & development, and others. The clinical diagnostics segment held the largest proteomics market share in 2022. However, the drug discovery & development segment is expected to register the highest CAGR of 14.4% during 2022-2030.End User -Based Insights
Based on end user, the market is segmented into pharmaceutical & biotechnology companies, research & clinical laboratories, hospitals, others. The pharmaceutical & biotechnology companies segment held the largest proteomics market share in 2022. However, the research & clinical laboratories segment is estimated to register the highest CAGR of 14.5% during 2022-2030.Leading players are implementing strategies such as expansion, partnership, launch of new products, and acquisition of a new customer base for tapping prevailing business opportunities.
- In January 2022, Seer, Inc. announced the debut of the Centers of Excellence program and the commercial release of the Proteograph Product Suite. The Proteograph Product Suite provides unbiased, unmatched access to the proteome. The approach uses uniquely designed nanoparticles to produce a breakthrough product that enables rapid, thorough, and unbiased large-scale proteomics.
- In February 2021, Agilent Technologies Inc. launched the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit, designed for the qualitative detection of immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum or plasma.
- In February 2021, Poochon Scientific, LLC acquired a new Thermo Orbitrap Exploris 240 mass spectrometer that has BioPharma option and FAIMS Pro interface. It is a versatile, new-generation, high-resolution mass spectrometer that offers exceptional performance for proteomics, metabolomics, and biopharmaceutical characterization.
Table of Contents
1. INTRODUCTION
4. PROTEOMICS MARKET LANDSCAPE
5. PROTEOMICS MARKET - KEY MARKET DYNAMICS
6. PROTEOMICS MARKET - GLOBAL MARKET ANALYSIS
7. PROTEOMICS MARKET - REVENUE AND FORECASTS TO 2028 - INSTRUMENT
8. PROTEOMICS MARKET - REVENUE AND FORECASTS TO 2028 - REAGENTS
9. PROTEOMICS MARKET - REVENUE AND FORECASTS TO 2028 - SERVICES AND SOFTWARE
10. PROTEOMICS MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
11. PROTEOMICS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
12. IMPACT OF COVID-19 PANDEMIC ON GLOBAL PROTEOMICS MARKET
13. INDUSTRY LANDSCAPE
14. PROTEOMICS MARKET, KEY COMPANY PROFILES
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Proteome Sciences
- Biognosys
- Creative Proteomics
- Shantani
- Olink
- SomaLogic Operating Co., Inc.
- QUANTUM-SI INCORPORATED
- Proteomics International
- Promise Proteomics
- SCIEX
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | March 2024 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 27.07 Billion |
| Forecasted Market Value ( USD | $ 75.03 Billion |
| Compound Annual Growth Rate | 13.6% |
